All In Biotech

NDA 209478 · Cmp Dev LLC

Carospir

Spironolactone · Oral · Aldosterone Antagonist

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 4, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

286

52 Phase 3, 28 recruiting

FAERS reports

114,068

86,569 serious, 13,594 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 28, 2026.

Spironolactone oral suspension is an antagonist of aldosterone indicated for: the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ) use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions ( 1.3 ) 1.1 Heart Failure Spironolactone oral suspension is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure. Spironolactone oral suspension is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone oral suspension is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management,...

Mechanism: Spironolactone and its active metabolites are specific pharmacologic antagonists of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents that act more proximally in the renal tubule.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CAROSPIR · SPIRONOLACTONE 25MG/5ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Spironolactone" as an intervention, any sponsor and status, largest first.

All 286 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea9,056
  • fatigue7,400
  • nausea6,911
  • diarrhoea6,535
  • acute kidney injury5,703
  • dizziness5,651
  • headache5,543
  • off label use5,180
  • drug ineffective4,907
  • hypotension4,890
  • fall4,218
  • death4,158

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004925
20051,121
20061,073
20071,069
20081,201
20091,459
20101,968
20112,150
20122,739
20132,708
20143,550
20155,261
20166,809
20176,304
20187,722
20198,404
20207,887
20217,806
20227,969
20238,769
20249,708
20259,761
20267,704

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Carospir (Spironolactone)

2024 spending

$186K

Beneficiaries

91

291 claims

Per beneficiary

$2,044

$3.35 per unit

View as table
YearSpending
2020$235,444
2021$355,190
2022$475,186
2023$567,507
2024$186,000

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,059 on PubMed

Sponsor: Cmp Dev LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.